N/A
N=13
Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Tachycardia Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT01764711 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Alldosterone Increase in Response to Adrenocorticotropin Hormone (ACTH). — 52.5; 57.9 nanograms/dL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cosyntropin administration (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University
- Primary completion
- Dec 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Alldosterone Increase in Response to Adrenocorticotropin Hormone (ACTH). |
52.5; 57.9 | — |
Summary
This study is to determine different chemical levels in the blood during a low salt diet. This study will compare normal volunteers to those with Postural Tachycardia Syndrome (POTS)
Eligibility Criteria
Inclusion Criteria
Subjects will be enrolled in the parent study "Dietary Salt in Postural Tachycardia Syndrome" during the "LOW SALT" phase
Postural Tachycardia Syndrome Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center Increase in heart rate ≥30 beats/min with position change from supine to standing (10 minutes) Chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
- Control Subjects
- Healthy, non-obese, non-smokers without orthostatic tachycardia
- Selected to match profiles of POTS patients (gender, age)
- Not using vasoactive medication
- Age between 18-50 years
- Male and female subjects are eligible.
- Able and willing to provide informed consent
Exclusion Criteria
- Overt cause for postural tachycardia (such as acute dehydration)
- Inability to give, or withdrawal of, informed consent
- pregnant
- Other factors which in the investigator's opinion would prevent the subject from completing the protocol.
Data sourced from ClinicalTrials.gov (NCT01764711). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.